Quadrature Capital’s AbCellera Biologics ABCL Stock Holding History

Quadrature Capital’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,972	Closed	-$133K	–	1547
2026 Q1	$133K	Sell	37,972 -167,123	-81%	-$601K	﹤0.01%	1189
2025 Q4	$701K	Buy	+205,095	New	+$916K	0.01%	609
2025 Q2	–	Sell	-14,584	Closed	-$32.4K	–	1003
2025 Q1	$32.4K	Sell	14,584 -21,872	-60%	-$62.7K	﹤0.01%	1010
2024 Q4	$107K	Sell	36,456 -23,161	-39%	-$64.5K	﹤0.01%	913
2024 Q3	$154K	Buy	59,617 +45,688	+328%	+$127K	﹤0.01%	809
2024 Q2	$41.4K	Buy	+13,929	New	+$52.7K	﹤0.01%	1080

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Quadrature Capital's ABCL Position: Q2 2026 in Review

Quadrature Capital sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 37,972 shares — an estimated $133K sold.

Quadrature Capital first reported a position in ABCL in Q2 2024 and held it in 6 quarters. The position peaked at $701K in Q4 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Quadrature Capital reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 37,972 AbCellera Biologics shares in Q2 2026, an estimated $133K.
Quadrature Capital first reported a position in AbCellera Biologics in Q2 2024 and held it in 6 quarters.
Quadrature Capital's AbCellera Biologics position peaked at $701K in Q4 2025.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.